Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study
2017; Elsevier BV; Volume: 29; Issue: 3 Linguagem: Inglês
10.1093/annonc/mdx767
ISSN1569-8041
AutoresJosep Tabernero, Rebecca R. Hozak, Takayuki Yoshino, Allen Lee Cohn, Radka Obermannová, G. Bodoky, Rocio García‐Carbonero, Tudor‐Eliade Ciuleanu, David C. Portnoy, Jana Prausová, Kei Muro, Robert W. Siegel, Robert J. Konrad, Haojun Ouyang, Symantha Melemed, D. Ferry, Federico Nasroulah, Eric Van Cutsem,
Tópico(s)Hepatocellular Carcinoma Treatment and Prognosis
ResumoThe phase III RAISE trial (NCT01183780) demonstrated that the vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody ramucirumab plus 5-fluororuracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo + FOLFIRI as second-line metastatic colorectal cancer (mCRC) treatment. To identify patients who benefit the most from VEGFR-2 blockade, the RAISE trial design included a prospective and comprehensive biomarker program that assessed the association of biomarkers with ramucirumab efficacy outcomes.
Referência(s)